DE69806408D1 - Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten - Google Patents

Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten

Info

Publication number
DE69806408D1
DE69806408D1 DE69806408T DE69806408T DE69806408D1 DE 69806408 D1 DE69806408 D1 DE 69806408D1 DE 69806408 T DE69806408 T DE 69806408T DE 69806408 T DE69806408 T DE 69806408T DE 69806408 D1 DE69806408 D1 DE 69806408D1
Authority
DE
Germany
Prior art keywords
rpos
sup
attenuated
bacteria
phentotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69806408T
Other languages
English (en)
Other versions
DE69806408T2 (de
Inventor
Curtiss, Iii
A Nickerson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Louis University
Washington University in St Louis WUSTL
Original Assignee
St Louis University
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Louis University, Washington University in St Louis WUSTL filed Critical St Louis University
Publication of DE69806408D1 publication Critical patent/DE69806408D1/de
Application granted granted Critical
Publication of DE69806408T2 publication Critical patent/DE69806408T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/22—Processes using, or culture media containing, cellulose or hydrolysates thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/879—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y10S435/897—Streptomyces griseus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69806408T 1997-11-14 1998-11-13 Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten Expired - Lifetime DE69806408T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/970,789 US6024961A (en) 1997-11-14 1997-11-14 Recombinant avirulent immunogenic S typhi having rpos positive phenotype
PCT/US1998/024295 WO1999025387A1 (en) 1997-11-14 1998-11-13 Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotype

Publications (2)

Publication Number Publication Date
DE69806408D1 true DE69806408D1 (de) 2002-08-08
DE69806408T2 DE69806408T2 (de) 2003-02-27

Family

ID=25517522

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69806408T Expired - Lifetime DE69806408T2 (de) 1997-11-14 1998-11-13 Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten

Country Status (12)

Country Link
US (3) US6024961A (de)
EP (1) EP1030690B1 (de)
JP (1) JP2001523649A (de)
KR (1) KR20010024650A (de)
AT (1) ATE219948T1 (de)
AU (1) AU736242B2 (de)
CA (1) CA2309925C (de)
DE (1) DE69806408T2 (de)
DK (1) DK1030690T3 (de)
ES (1) ES2181306T3 (de)
IL (1) IL136131A0 (de)
WO (1) WO1999025387A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312934T1 (de) * 1995-06-07 2005-12-15 Univ Washington Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
US6585975B1 (en) 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
AU772356B2 (en) * 1998-12-04 2004-04-22 Aventis Pasteur Limited Two-step immunization procedure against chlamydia infection
JP3655510B2 (ja) * 1999-10-29 2005-06-02 株式会社東芝 ネットワーク接続装置、通信装置及びネットワーク接続方法
WO2001032697A2 (en) * 1999-11-05 2001-05-10 L'unite De Recherche En Biologie Moleculaire (Urbm) Des Facultes Universitaires Notre Dame De La Paix (Fundp) Virulence genes and proteins from brucella melitensis, and their use
US6207167B1 (en) * 1999-12-09 2001-03-27 Crystal Biotechnology Research And Development Co., Ltd. Chicken leucocytozoon vaccine
DK1272213T3 (da) * 2000-04-06 2006-07-10 Seer Pharmaceuticals Llc Mikrobielt afgivelsessystem
US6780405B1 (en) * 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US6872547B1 (en) * 2000-10-11 2005-03-29 Washington University Functional balanced-lethal host-vector systems
US20040137003A1 (en) * 2001-04-30 2004-07-15 Curtiss Iii Roy Regulated antigen delivery system (rads)
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US20050096283A1 (en) * 2001-12-14 2005-05-05 The Regents Of University Of California Methods of inhibiting fertility
US20050075298A1 (en) * 2002-01-31 2005-04-07 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
CA2526895A1 (en) 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7270961B2 (en) * 2002-04-16 2007-09-18 Hui Sunny Chang In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes
US20050220818A1 (en) * 2002-06-21 2005-10-06 Wellstat Biologics Corporation Administration of therapeutic viruses
DE10326187A1 (de) * 2003-06-06 2005-01-05 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Zellen als Träger für Bakterien
US7390646B2 (en) * 2003-09-17 2008-06-24 The Regents Of The University Of California Bacterial vectors and methods of use thereof
EP1789094B1 (de) 2004-08-13 2014-12-10 MARSHALL, Barry J. Bakterielles abgabesystem
US8029777B2 (en) * 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
WO2007120368A2 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
WO2007106073A2 (en) 2006-03-02 2007-09-20 University Of Massachusetts Modified pathogens for use as vaccines
KR100749493B1 (ko) * 2006-03-22 2007-08-14 한국원자력연구원 대장균에서 ｒｐｏＳ 유전자의 발현을 조절함으로서프로피온산에 대한 미생물 감수성을 증진시키는 방법
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20100317084A1 (en) * 2007-05-10 2010-12-16 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
EP2150616A4 (de) 2007-05-10 2011-07-27 Univ Arizona Geregelte antigensynthese und/oder geregelte attenuation zur verbesserung der impfstoff immunogenität und/oder -sicherheit
ES2323839B2 (es) * 2007-07-24 2010-07-08 Universidad Complutense De Madrid Cepa viva atenuada de salmonella enterica serovar choleraesuis como vacuna y vehiculo vacunal para el ganado porcino.
US8465755B2 (en) * 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
US8057992B2 (en) * 2007-11-07 2011-11-15 Auburn University Methods for identifying peptides that bind to intact oocytes
EP2280723B1 (de) 2008-04-07 2012-07-25 Auburn University Verfahren für die speziesspezifische immunkontrazeption bei tieren
CA2726293C (en) * 2008-06-03 2017-02-28 University Of Maryland, Baltimore Non-hemolytic clya for excretion of proteins
WO2010045620A1 (en) * 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US9163219B2 (en) * 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
GB2483595B (en) 2009-05-22 2017-03-29 The Arizona Board Of Regents For And On Behalf Of Arizona State Univ Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) * 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
WO2011091291A1 (en) 2010-01-22 2011-07-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
EP2711019B1 (de) 2010-03-22 2016-11-02 Auburn University Phagenkonstrukte, Sequenzen und antigene Zusammensetzungen zur immunologischen Schwangerschaftsverhütung von Tieren
WO2011150421A2 (en) 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
US20120156215A1 (en) 2010-06-21 2012-06-21 Auburn University Phage-GnRH Constructs, Their Mimics, Antigenic Compositions, and Sequences for Immunocontraception of Animals and Other Applications
WO2012003460A2 (en) 2010-07-02 2012-01-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Compositions and methods for bacterial lysis and neutral lipid production
US8940297B2 (en) 2010-12-22 2015-01-27 Saint Louis University Expression of thrombin variants
EP2675460A4 (de) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc Behandlung von fettgewebe unter dem kinn
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN106222123B (zh) * 2016-07-29 2019-06-07 扬州大学 鸡白痢沙门菌三基因敲除减毒突变株制备及其应用
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CA3069523A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
KR20210030973A (ko) 2018-07-11 2021-03-18 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN110157723B (zh) * 2019-05-10 2021-10-01 四川大学 一步同源重组法在鼠伤寒沙门菌必须基因敲除中的应用
WO2021062037A1 (en) 2019-09-24 2021-04-01 Auburn University Phage-peptide constructs for stimulation of an anti-cancer immune response against cd47
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
KR20240015033A (ko) * 2022-07-25 2024-02-02 충남대학교산학협력단 인터루킨-7 분비를 위한 재조합 발현 벡터 및 이로형질전환된 약독화 살모넬라 균주

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US5387744A (en) * 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
US5294441A (en) * 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
ATE121785T1 (de) * 1987-10-07 1995-05-15 Univ Washington Verfahren zur erhaltung eines erwünschten rekombinanten gens in einer genetischen zellpopulation.
WO1992009684A1 (en) * 1990-11-21 1992-06-11 Washington University Recombinant avirulent salmonella antifertility vaccines
AU6705594A (en) * 1993-04-15 1994-11-08 Washington University Compositions of antigen containing recombinant salmonella, their use in anti-malarial vaccines and method for their preparation
AU674584B2 (en) * 1993-06-02 1997-01-02 Tvw Telethon Institute For Child Health Research Cryptic peptides for use in inducing immunologic tolerance
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype

Also Published As

Publication number Publication date
CA2309925C (en) 2010-06-01
CA2309925A1 (en) 1999-05-27
EP1030690B1 (de) 2002-07-03
IL136131A0 (en) 2001-05-20
WO1999025387A1 (en) 1999-05-27
KR20010024650A (ko) 2001-03-26
US20030031683A1 (en) 2003-02-13
JP2001523649A (ja) 2001-11-27
AU736242B2 (en) 2001-07-26
EP1030690A1 (de) 2000-08-30
AU1459599A (en) 1999-06-07
ATE219948T1 (de) 2002-07-15
US6383496B1 (en) 2002-05-07
ES2181306T3 (es) 2003-02-16
US7083794B2 (en) 2006-08-01
US6024961A (en) 2000-02-15
DK1030690T3 (da) 2002-10-21
DE69806408T2 (de) 2003-02-27

Similar Documents

Publication Publication Date Title
DE69806408D1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
Saxena et al. Pre-existing immunity against vaccine vectors–friend or foe?
DE69922937D1 (de) Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten
EP0465560A4 (en) Vaccines containing avirulent phop-type microorganisms
BR9712852A (pt) Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
YU12894A (sh) Farmaceutski preparat na bazi nukleinske kiseline
AU2785089A (en) Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
WO1998056901A3 (en) Live attenuated vaccines
CY1107950T1 (el) Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι
DE69322092D1 (de) Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
Gahan et al. Impact of plasmid stability on oral DNA delivery by Salmonella enterica serovar Typhimurium
DE69533102D1 (de) Analog von haemophilus hin47 mit verminderter protease aktivität
Dunstan et al. In vitro and in vivo stability of recombinant plasmids in a vaccine strain of Salmonella enterica var. Typhimurium
ATE346931T1 (de) Clostridium perfringens impfstoff
Atkins et al. Recombinant Salmonella vaccines for biodefence
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
YU49995A (sh) Polinukleotidna vakcina za virus herpesa
Fu et al. Controlled expression of lysis gene E by a mutant of the promoter pL of the thermo‐inducible λcI857‐pL system
WO1994025598A3 (en) Methods and compositions for salmonella-based vaccines
EP1905834A3 (de) Virulenzgene, Proteine und deren Verwendung
GB2331521A (en) Vaccine preparations
ES8304801A1 (es) Un metodo para preparar una vacuna contra vibrio anguillarum
AU1853995A (en) Vaccine compositions
IL67818A0 (en) Vaccines comprising ozone inactivated organisms and their production
KR20100044466A (ko) 환경에서 생존이 불가능한 박테리아를 함유하는 생백신 조성물